Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorLope-Piedrafita, Silvia
dc.contributor.authorLucas-Parra, Maria
dc.contributor.authorMarazuela , Paula
dc.contributor.authorBonaterra Pastra, Anna
dc.contributor.authorSolé, Montse
dc.contributor.authorCastellote Bellés, Laura
dc.contributor.authorPancorbo, Olalla
dc.contributor.authorRodriguez-Luna, David
dc.contributor.authorHernandez Guillamon, Maria Mar
dc.date.accessioned2024-10-02T08:34:43Z
dc.date.available2024-10-02T08:34:43Z
dc.date.issued2024-07-29
dc.identifier.citationBonaterra-Pastra A, Solé M, Lope-Piedrafita S, Lucas-Parra M, Castellote L, Marazuela P, et al. The presence of circulating human apolipoprotein J reduces the occurrence of cerebral microbleeds in a transgenic mouse model with cerebral amyloid angiopathy. Alzheimers Res Ther. 2024 Jul 29;16:169.
dc.identifier.issn1758-9193
dc.identifier.urihttps://hdl.handle.net/11351/12002
dc.descriptionApolipoprotein J; Cerebral amyloid Angiopathy; Cerebral microbleeds
dc.description.abstractBackground Cerebral amyloid angiopathy (CAA) is characterized by amyloid-β (Aβ) deposition in cerebral vessels, leading to lobar cerebral microbleeds (CMB) and intracerebral hemorrhages (ICH). Apolipoprotein J (ApoJ) is a multifunctional chaperone related to Aβ aggregation and clearance. Our study investigated the vascular impact of chronic recombinant human Apolipoprotein J (rhApoJ) treatment in a transgenic mouse model of β-amyloidosis with prominent CAA. Methods Twenty-month-old APP23 C57BL/6 mice received 25 doses of rhApoJ (1 mg/kg) (n = 9) or saline (n = 8) intraperitoneally for 13 weeks, while Wild-type (WT) mice received saline (n = 13). Postmortem brains underwent T2*-weighted magnetic resonance imaging (MRI) to detect hemorrhagic lesions. Aβ levels and distribution, cerebral fibrinogen leakage, brain smooth muscle actin (sma), and plasma matrix metalloproteinases and inflammatory markers were analyzed after treatments. Additionally, plasma samples from 22 patients with lobar ICH were examined to determine the clinical relevance of the preclinical findings. Results rhApoJ-treated APP23 presented fewer cortical CMBs (50–300 μm diameter) (p = 0.012) and cortical larger hemorrhages (> 300 μm) (p = 0.002) than saline-treated mice, independently of Aβ brain levels. MRI-detected hemorrhagic lesions correlated with fibrinogen cerebral extravasation (p = 0.011). Additionally, rhApoJ-treated mice presented higher number of sma-positive vessels than saline-treated mice (p = 0.038). In rhApoJ-treated mice, human ApoJ was detected in plasma and in occasional leptomeningeal vessels, but not in the parenchyma, suggesting that its mechanism of action operates through the periphery. The administration of rhApoJ induced an increase in plasma Groα (p = 0.035) and MIP-1α (p = 0.035) levels, while lower MMP-12 (p = 0.046) levels, compared to the saline-treated group. In acute lobar ICH patients, MMP-12 plasma levels correlated with larger hemorrhage volume (p = 0.040) and irregular ICH shape (p = 0.036). Conclusions Chronic rhApoJ treatment in aged APP23 mice ameliorated CAA-related neurovascular damage by reducing the occurrence of CMB. We propose that rhApoJ may prevent blood-brain barrier (BBB) leakage and CMB appearance partly through circulating MMP-12 modulation.
dc.language.isoeng
dc.publisherBMC
dc.relation.ispartofseriesAlzheimer's Research & Therapy;16
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectApolipoproteïnes
dc.subjectHemorràgia cerebral
dc.subjectRatolins transgènics
dc.subjectMalalties cerebrovasculars - Tractament
dc.subject.meshMice, Transgenic
dc.subject.meshCerebral Hemorrhage
dc.subject.meshCerebral Amyloid Angiopathy
dc.subject.mesh/drug therapy
dc.subject.meshAmyloid beta-Peptides
dc.titleThe presence of circulating human apolipoprotein J reduces the occurrence of cerebral microbleeds in a transgenic mouse model with cerebral amyloid angiopathy
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1186/s13195-024-01541-5
dc.subject.decsratones transgénicos
dc.subject.decshemorragia cerebral
dc.subject.decsangiopatía amiloide cerebral
dc.subject.decs/farmacoterapia
dc.subject.decspéptidos beta amiloides
dc.relation.publishversionhttps://doi.org/10.1186/s13195-024-01541-5
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Bonaterra-Pastra A, Lucas-Parra M, Marazuela P, Hernández-Guillamon M] Grup de Recerca de Malalties Neurovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Solé M] Grup de Recerca de Malalties Neurovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Departament of Bioquímica i Biologia Molecular, Institut de Neurociències, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Lope-Piedrafita S] Departament de Ressonància Magnètica Nuclear, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Castellote L] Servei de Bioquímica Clínica, Laboratoris Clínics, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Pancorbo O, Rodríguez-Luna D] Grup de Recerca en Ictus, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain
dc.identifier.pmid39069622
dc.identifier.wos001279310700001
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2017-2020/PI17%2F00275
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2017-2020/PI20%2F00465
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PEICTI2021-2023/PI23%2F00082
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PEICTI2021-2023/RD21%2F0006%2F0007
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record